Jiangsu HengRui registers Phase III trial of HRS-6209 plus letrozole in advanced breast cancer
The study, led by Jiangsu HengRui Medicine Co., Ltd., plans to enroll 1050 participants and begin on November 20, 2026. It compares HRS-6209 plus letrozole with dalpciclib or palbociclib plus aromatase inhibitor in patients with advanced or metastatic breast cancer who have not received prior systemic treatment.
Primary source
ClinicalTrials.gov registry record, October 26, 2026
A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer
Read the source: A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation